Abatacept Versus Adalimumab Head-to-Head

• Status: Completed
• Trial end date: 2012-11-01

Summary

The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive

• Phase: Phase 3

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Abatacept; Adalimumab